Use of a mobile application for the control of anticoagulation with warfarin
a cluster randomized controlled clinical trial - Ijui/RS/Brazil
DOI:
https://doi.org/10.1590/s2175-97902022e19153Palavras-chave:
Mobile applications, Clinical trial, Warfarin, Outpatient monitoringResumo
To evaluate the effectiveness of an anticoagulation protocol adapted in a mobile application (appG) for patients using warfarin. This was a cluster randomized controlled clinical trial carried out in basic health centers of Ijui, RS, Brazil, between April and October 2017. The appG was installed on the cell phones of all physicians belonging to the intervention group. Primary outcomes were bleeding and thrombosis, and secondary outcomes were changes in the dose of warfarin, use of new drugs, drug interactions, search for health services, and remaining on the target international normalized ratio. Thirty-three patients belonging to 11 basic health centers were included in this study. From these, 15 patients were in the intervention group which used the appG, and 18 were in the control group. After 6 months, patients in the appG group had fewer bleeding events (7% versus 50%, p-value=0.028) and a lower weekly dose of warfarin (29.3 ± 9.7 mg versus 41.7 ± 12.5 mg, p-value=0.030) when compared to the control group. The anticoagulation protocol adapted in a mobile app reduced bleeding in patients using warfarin.
Downloads
Referências
Agnelo P, Alexandra D, Matias S. Monitoring of patients under oral anticoagulation in a primary care unit. Rev Port Cardiol. 2014;33(7-8):397-401.
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and Management of the Vitamin K Antagonists. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 Suppl):160S-98S.
Bartholomay E, Polli I, Borges AP, Kalil C, Arroque A, Kholer I, et al. Prevalence of oral anticoagulation in atrial fibrillation. Clinics. 2014;69(9):615-20.
Burke LE, Ma J, Azar KM, Bennett GG, Peterson ED, Zheng Y, et al. Current science on consumer use of mobile health for cardiovascular disease prevention: a scientific statement from the American Heart Association. Circulation. 2015;132(12):1157-213.
Castro TA, Heineck I. Interventions to improve anticoagulation with warfarin. Ther Drug Monit. 2012;34(2):209-16.
Christensen TD, Johnsen SP, Hjortdal VE, Hasenkam JM. Self-management of oral anticoagulant therapy: a systematic review and meta-analysis. Int J Cardiol. 2007; 118(1):54-61.
Colet, CF, Amador, TA, Heineck, I. Drug interactions and adverse events in a cohort of warfarin users attending public health clinics. Int J Cardiovasc Sci. 2018a; [online].ahead print, PP.0-0.
Colet, CF, Amador, TA, Heineck, I. Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil. Braz J Pharm Sci. 2018b;54(3):e17738.
Furie B. Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N Engl J Med. 2013;369(24):2345-6.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2013;369(22):2093-104.
Go AS, Hylek EM, Borowsky LH, Philips KA, Selbu JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999;131(12):927-34.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus Warfarin in patients with atrial fibrillation. N Engl J Med . 2011;365(10):981-92.
Henegahn C, Ward A, Perera R, Self-Monitoring Trialist Collaboration, Bankhead C, Fuller A, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet. 2012;379(9813):322-34.
Hospital of Clinics of Porto Alegre. Oral Anticoagulation Assistance Protocol, PRT-0008. Hospital of Clinics of Porto Alegre, RS - 2012.
Inoue H, Kodani E, Atarashi H, Okumura K, Yamashita T, Okuyama Y, Origasa HJ. Time in Therapeutic Range and Disease Outcomes in Elderly Japanese Patients With Nonvalvular Atrial Fibrillation. Circ J. 2018;82(10):2510-17.
Jenner KM, Simmons BJ, Delate T, Clark NP, Kurz D, Witt DM. An education program for patient self-management of warfarin. Perm J. 2015;19(4):33-8.
Leiria TLL, Pellanda L, Miglioranza MH, Sant’Anna RT, Becker LS, Magalhães E, et al. Warfarin and emfprocumone: experience of an anticoagulation clinic. Arq Bras Cardiol. 2010;94(1):41-5.
Mansur AP, Takada JY, Avakian SD, Strunz CMC. Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation. Clinics . 2012;67(6):543-6.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med . 2011;365(10):883-91.
Pelegrino FM, Dantas RAS, Corbi ISA, Carvalho ARS. Demographic and clinical socioeconomic profile of patients using oral anticoagulants. Rev Gaúcha Enferm. 2010;31(1):123-8.
Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, et al. Can we predict daily adherence to warfarin?: Results from the International Normalized Ratio adherence and genetics (IN-Range) study. Chest . 2010;137(4):883-9.
Raghu A, Praveen D, Perirs D, Trasassenko L, Clifford G. Engineering a mobile health tool for resource-poor settings to assess and manage cardiovascular disease risk: SMARThealth study. BMC Med Inform Decis Mak. 2015;15:1-36.
Schimidt L, Spechman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis. 2003;15(3):213-6.
Serrano Junior CV, Fenelon G, Soeiro AM, Nicolau JC, Piegas LS, Montenegro ST, et al. Brazilian Society of Cardiology. Brazilian Guidelines on Platelet Antiplatelet Agents and Anticoagulants in Cardiology. Arq Bras Cardiol . 2013;101(3 Suppl 3):1-93.
Stephan LS, Dytz Almeida E, Guimaraes RB, AG Law, Mathias RG, Assis MV, et al. Processes and recommendations for creating mHealth apps for low-income populations. JMIR Mhealth Uhealth. 2017;5(4):e41.
Suarez-Kurtz G, Botton MR. Pharmacogenetics of coumarin anticoagulants in Brazilians. Expert Opin Drug Metab Toxicol. 2015;11(1):67-79.
Tadros R, Shakib S. Warfarin: indications, risks and drug interactions. Aust Fam Physician. 2010;39(7):476-9.
Van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest . 2006;129(5):1155-66.
Zhao Z, Kansal S, Bukaveckas BL. Smartwarf - a portable automated warfarin dosing tool. In: CTS 09: Proceedings of the 2009 Internation Symposium on Collaborative Technologies and Systems. Waashington, DC, USA: IEEE Computer Society. 2009;Mai: 348-55.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
